Episode Highlights a Truly Remarkable Patient Story Spanning 79 Years Video features 79-year-old Norma Coles, believed to be ...

Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic Dermatitis Third Quoin Patent Application for Netherton Syndrome If Granted Company ...

Quoin Pharmaceuticals Ltd. has filed a U.S. patent application for new topical formulations aimed at treating several skin diseases, specifically Netherton Syndrome (NS) and Peeling Skin Syndrome.

A diagnosis of Netherton syndrome was made and the patient was started on antihistamines, emollients, and 10% urea. In our case, the patient presented at age 17 years. The history of his ...

Quoin Pharmaceuticals (QNRX) announces additional highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome ...

Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the company's NETHERTON NOW website ASHBURN, Va., April ...

Quoin’s lead product, QRX003, is currently being tested in four Netherton Syndrome clinical trials. Three of these trials are being conducted under Quoin’s open Investigational New Drug (IND ...

SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic Dermatitis Third Quoin Patent Application for Netherton Syndrome If Granted Company Would have Patent Protection for QRX003 for Netherton ...

Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the company’s NETHERTON NOW website “Norma’s ...